Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of nimotuzumab plus radiotherapy in elderly patients with locally advanced squamous cell carcinoma of the head and neck
ChiCTR2600132546Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Objective response rate. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
nimotuzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2600132546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132546.